Loxo Oncology prices upsized IPO at $13, the midpoint of the range

By
A A A

Loxo Oncology, an early-stage biotech developing targeted therapies to treat solid tumors, raised $68 million by offering 5.3 million shares (vs. 4.4 million originally planned) at $13, the midpoint of the $12 to $14 range. Loxo Oncology will list on the NASDAQ under the symbol LOXO. Cowen & Company and Stifel acted as joint bookrunners on the deal.




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: LOXO

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

33,110,376
  • $113.99 ▲ 1.77%
25,034,179
    $17.98 unch
24,486,872
  • $7.41 ▲ 2.07%
20,864,535
  • $7.39 ▼ 2.76%
18,600,501
  • $8.30 ▼ 0.36%
17,530,211
  • $8.14 ▲ 3.17%
17,299,208
  • $93.79 ▲ 2.74%
14,669,760
  • $25.78 ▼ 0.19%
As of 12/26/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com